32. Taylor M. Participants in rogue herpes vaccine research take legal action. Kaiser Health News. March 13, 2018. Available at: https://khn.org/news/participants-in-rogue-herpes-vaccine-research-take-legal-action/. Accessed June 25, 2018.
33. Oseso L, Magaret A. S, Jerome K. R, Fox J, Wald A. Attitudes and willingness to assume risk of experimental therapy to eradicate genital herpes simplex virus infection.
34. Phipps W, Saracino M, Magaret A, Selke S, Remington M, Huang M. L., Warren T, Casper C, Corey L, Wald A. Persistent genital herpes simplex virus-2 shedding years following the first clinical episode.
35. Tronstein E, Johnston C, Huang M. L., Selke S, Magaret A, Warren T, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection.
36. Johnston C, Zhu J, Jing L, Laing K. J, McClurkan C M., Klock A, Diem K, Jin L, Stanaway J, Tronstein E, Kwok W. W., Huang M. L., Selke S, Fong Y, Magaret A, Koelle D. M., Wald A, Corey L. Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection.
37. Xu F, Sternberg M. R., Kottiri B. J., McQuillan G. M., Lee F. K., Nahmias A. J., Berman S. M., Markowitz L. E. Trends in herpes simplex virus
38. Satterwhite C. L., Torrone E, Meites E, Dunne E. F., Mahajan R., Ocfemia M. C., Su J, Xu F, Weinstock H. Sexually transmitted infections among U.S. women and men: prevalence and incidence estimates, 2008.
39. McQuillan G., Kruszon-Moran D., Flagg E. W., Paulose-Ram R.
40. Bernstein